Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKanabo Grp Plc Regulatory News (KNB)

  • This share is currently suspended. It was suspended at a price of 0.225

Share Price Information for Kanabo Grp Plc (KNB)

Share Price is delayed by 15 minutes
Get Live Data
0.225    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £1.42m
KNB Live PriceLast checked at - London Stock Exchange

Intraday Kanabo Grp Plc Share Chart

Contract Extension

9 Jun 2022 07:00

RNS Number : 2925O
Kanabo Group PLC
09 June 2022
 

 

Kanabo Group Plc.

("Kanabo" or the "Company")

 

Contract Extension

 

The GP Service Extends its Contact with a Major UK Food Retailer

 

Kanabo Group Plc. (LON: KNB), announces an extension to its existing contract between the GP Service and one of the United Kingdom's ("UK") largest group of retail businesses including food retail, wholesale, e-pharmacy, insurance, and legal services.

 

The recently acquired GP Service, originally partnered with the retailer in 2019, for the provision of general medical assistance for its members. The original agreement was limited to the submission of the patient's medical history online where the GP Service doctors would review information provided by the patient and complete the prescription for the retailer to arrange subsequent fulfilment and delivery of any approved medication.

 

Under the new Contract Extension, the GP Service will also now provide live Video Consultation services with prescriptions available for collection through the GP Service partner network of over 4,000 pharmacies across the UK. Users will normally see a doctor and may receive a prescription for collection on the same video call. In addition to prescription services, the GP Service will also provide fit notes and referrals.

 

Consultations will be available between 8am and 8pm, Monday to Sunday, 365 days a year. Consultations are usually available within 30 minutes with approximately 95% of all prescriptions available within 60 minutes of the consultation.

 

Atul Devani, CEO of the GP Service commented: "The extension of this agreement reflects the successful relationship we have had since we began working together in 2019. Our integration with the NHS summary care records ensures our services are both safe & secure and we now look forward to extending our services to include virtual GP consultations with automated digital prescriptions."

 

Kanabo, CEO, Avihu Tamir, said: "I am delighted to see this contract extension with a major retailer in the UK, which goes a long way to validating our rationale for the acquisition earlier this year. The GP Service is an innovative Telemedicine Provider, that forms an integral part of the overall strategy at Kanabo, and I look forward to extending our services in the UK further over the coming months and years."

 

 

For further information, please visit http://www.kanabogroup.com/ or https://www.voxmarkets.co.uk/listings/LON/KNB or contact the following:

 

Kanabo Group Plc

Via Vox Markets

Avihu Tamir, CEO

Peterhouse Capital Ltd (Financial Adviser)

Tel: +44 (0)20 7469 0930

Eran Zucker / Lauren Riley

Vox Markets (Investor Relations)

KanaboGroup@voxmarkets.co.uk

Kat Perez

kperez@voxmarkets.co.uk

 

 

 

About Kanabo Group Plc

Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers.

 

It has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFIFEERDIAIIF
Date   Source Headline
18th Jan 20227:00 amRNSMateria Announces Trading Update for 4Q22
6th Jan 20224:41 pmRNSSecond Price Monitoring Extn
6th Jan 20224:36 pmRNSPrice Monitoring Extension
31st Dec 202111:41 amRNSTotal Voting Rights
31st Dec 202110:00 amRNSGrant of Options
30th Dec 20211:00 pmRNSAchievement of Milestones
16th Dec 20217:05 amRNSMateria Malta First Sales in Europe
15th Dec 20217:00 amRNSPatent Advancement
7th Dec 20217:00 amRNSSubmission for Bioavailability and Efficacy Trial
6th Dec 20213:45 pmRNSExercise of Options
6th Dec 20217:00 amRNSUK Moves to License e-cigarettes and vaporizers
30th Nov 20214:02 pmRNSTotal Voting Rights
29th Nov 202111:05 amRNSSecond Price Monitoring Extn
29th Nov 202111:00 amRNSPrice Monitoring Extension
26th Nov 202111:57 amRNSKanabo to present at Mello: 29 November 2021
4th Nov 20217:00 amRNSUpdate on Materia Acquisition
29th Oct 20217:00 amRNSTotal Voting Rights
22nd Oct 20217:00 amRNSHalf-year Report
7th Oct 20217:00 amRNSNew Partnership Agreement
30th Sep 20217:00 amRNSTotal Voting Rights
22nd Sep 20217:00 amRNSCBD Line Launched in the UK on HandpickedCBD.com
14th Sep 20217:05 amRNSMateria Receives Licence for Malta Facility
31st Aug 20211:51 pmRNSTotal Voting Rights
17th Aug 202111:05 amRNSSecond Price Monitoring Extn
17th Aug 202111:00 amRNSPrice Monitoring Extension
17th Aug 20217:00 amRNSUpdate: New contract signed by Materia
2nd Aug 20217:01 amRNSUpdate re: Investment & MoU with Hellenic Dynamics
30th Jul 202112:49 pmRNSTotal Voting Rights
26th Jul 202111:05 amRNSSecond Price Monitoring Extn
26th Jul 202111:00 amRNSPrice Monitoring Extension
26th Jul 20217:00 amRNSProposed Acquisition
22nd Jul 20213:32 pmRNSBlock Listing Application
14th Jul 20217:00 amRNSKanabo’s First Medical Cannabis Product in UK
8th Jul 20211:00 pmRNSIssue of Equity
30th Jun 20217:00 amRNSTotal Voting Rights
29th Jun 20217:00 amRNSAppointment of Director & Grant of Options
28th Jun 20213:41 pmRNSResult of AGM
25th Jun 20217:00 amRNSInitial Commercial Scale Production
24th Jun 20213:58 pmRNSIssue of Equity
17th Jun 20212:59 pmRNSIssue of Equity
4th Jun 20217:00 amRNSSupport for New Campaign
3rd Jun 202112:00 pmRNSNotice of AGM
2nd Jun 20219:26 amRNSAnnual Financial Report
26th May 20213:36 pmRNSAdmission of Placing Shares
24th May 20217:00 amRNSPlacing, Investment & MoU with Hellenic Dynamics
20th May 20217:00 amRNSNew EU GMP CBD Manufacturing Agreement
14th May 20212:00 pmRNSIssue of Equity
11th May 20211:09 pmRNSIssue of Equity
6th May 20212:00 pmRNSIssue of Equity
26th Apr 20213:03 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.